Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer

被引：2
|
作者：
Uehara, Yuji [1 ,2 ]
Hakozaki, Taiki [1 ,3 ,4 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[2] Tokyo Med & Dent Univ, Ctr Innovat Canc Treatment, Grad Sch Med & Dent Sci, Dept Precis Canc Med, Tokyo, Japan
[3] Waseda Univ, Fac Sci & Engn, Grad Sch Adv Sci & Engn, Tokyo, Japan
[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, 3-18-22 Honkomagome, Bunkyo, Tokyo, Japan
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 01期
关键词：
Immune checkpoint inhibitor (ICI); non-small cell lung cancer (NSCLC); gene rearrangement; biomarker; prognosis; OUTCOMES; IMMUNOTHERAPY; MUTATIONS; EFFICACY; BLOCKADE; NSCLC;
D O I：
10.21037/tlcr-22-872
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 10
页数：5
相关论文
共 50 条
  • [41] Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Chai, Rong
    Yin, Yipengchen
    Cai, Xuwei
    Fu, Xiaolong
    Zhang, Qin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Safety of Palliative Radiotherapy and Immune Checkpoint Inhibitors in Patients with Metastatic Non-Small Cell Lung Cancer
    Tjong, M.
    Ragulojan, M.
    Poon, I.
    Cheng, S.
    Doherty, M.
    Ung, Y.
    Cheung, P.
    Cheema, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S667 - S668
  • [43] Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
    Ayala de Miguel, P.
    Lopez Gallego, J.
    Gorospe Garcia, I.
    Illan Varella, A.
    Rivera Vargas, P. R.
    Posada Restrepo, A.
    Borrega Garcia, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients
    Duma, Narjust
    Azzouqa, Abdel-Ghani
    Yadav, Siddhartha
    Hoversten, Kahterine
    Reed, Clay
    Sitek, Andrea
    Enninga, Elizabeth
    Paludo, Jonas
    Kottschade, Lisa
    Mansfield, Aaron
    Manochakian, Rami
    Dronca, Roxana
    Adjei, Alex
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [45] Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
    Zaim, Remziye
    Redekop, W. Ken A.
    Uyl-de Groot, Carin A.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
    Li, Na
    Zheng, Huanrui
    Zheng, Bin
    Chen, Chaoxin
    Cai, Hongfu
    Liu, Maobai
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4503 - 4518
  • [47] Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lo Russo, G.
    Signorelli, D.
    Proto, C.
    Galli, G.
    Prelaj, A.
    Ferrara, R.
    Sommariva, M.
    Moro, M.
    Cancila, V.
    Ganzinelli, M.
    Brich, S.
    Sangaletti, S.
    Pruneri, G.
    Tripodo, C.
    Colombo, M. P.
    Rivoltini, L.
    Balsari, A.
    Sozzi, G.
    Boeri, M.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S245 - S245
  • [48] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei Yuxi
    Xu Yan
    Wang Mengzhao
    中华医学杂志英文版, 2023, 136 (13)
  • [49] Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer
    Itsuki Yuasa
    Masatsugu Hamaji
    Hiroaki Ozasa
    Yuichi Sakamori
    Hironori Yoshida
    Yojiro Yutaka
    Toshi Menju
    Toyohiro Hirai
    Hiroshi Date
    General Thoracic and Cardiovascular Surgery, 2023, 71 : 534 - 541
  • [50] Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Alfranca, Yolanda Lage
    Garcia, Maria Eugenia Olmedo
    Rueda, Ana Gomez
    Ballesteros, Pablo Alvarez
    Rodriguez, Diana Rosero
    Velasco, Marisa Torres
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
12345